| Cat.No. | Name | Information |
|---|---|---|
| M1539 | Omalizumab | Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) and to membrane-bound form of IgE (mIgE). |
| M1527 | Ofatumumab | Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation. |
| M1519 | Matuzumab | Matuzumab (EMD 72000) is a humanized monoclonal antibody that binds tightly to EGFR. |
| M1512 | Nimotuzumab | Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR. |
| M58441 | Sabirnetug | Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein. |
| M58439 | Ozekibart | Ozekibart is an anti-TNFRSF10B monoclonal antibody. |
| M58124 | Conbercept | Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc. |
| M55648 | TOUR006 | |
| M55641 | Cantuzumab | Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. |
| M55636 | ATI-1013 | ATI-1013 is a fully human, anti-nicotine monoclonal antibody. ATI-1013 is a proprietary compound that neutralizes nicotine in the blood. Studies in animals have shown that following an injection of nicotine, ATI-1013 blocks nicotine-induced increases in blood pressure, reduces nicotine levels in the brain by more than 90%, and reduces the vasoconstrictive peripheral effects of nicotine on blood vessels. |
| M55572 | NM5072 | NM5072 is a first-in-class anti-Properdin monoclonal antibody that selectively blocks the alternative pathway (AP) while maintaining the integrity of the classical pathway required for fending off infections. NM5072 selectively hinders the immune system components responsible for the disease, inhibiting alternative pathway cascades and preventing the lysis of PNH red blood cells (RBCs). |
| M55571 | Empasiprubart | Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. |
| M55570 | GT103 | GT103 is a novel, first-in-class fully human IgG3 monoclonal antibody that targets the tumor cell-protein complement factor H (CFH). GT103 binds a conformationally distinct epitope within a specific crucial functional domain on tumor cell bound CFH. Upon binding to CFH, the antibody triggers complement dependent cytotoxicity, resulting in tumor cell death. In mouse models, GT103 inhibits tumor growth and modulates the adaptive immune response, dramatically reducing the number of immune suppressive T regulatory cells and myeloid-derived suppressor cells in the tumor. |
| M55568 | Tarperprumig | Tarperprumig is an anti-ALB/CFP monoclonal antibody composed of 2 heavy chain variable regions linked together. |
| M55255 | APVO603 | APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. |
| M55254 | STAR-0310 | STAR-0310 is a novel OX40 antagonistic monoclonal antibody which has a potential best-in-class profile with a high affinity, potential for favorable safety and tolerability profile with low T cell depletion from ADCC or possible on-target cellular toxicity. |
| M55252 | FS120 | FS120 is a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 (4-1BB, TNFRSF9) and OX40 (CD134, TNFRSF4). FS120 has the potential to show activity in "cold" tumors and improve outcomes of existing immunotherapies by simultaneously agonizing CD137 and OX40. |
| M55251 | ATOR-1015 | ATOR-1015 is a human CTLA-4 x OX40 targeting IgG1 bispecific antibody with enhanced immune activation and tumor-directed activity for improved efficacy and reduced toxicity. ATOR-1015 induces T-cell activation and Treg depletion in vitro. |
| M55250 | YH002 | YH002 is a recombinant anti-OX40 (CD134, TNFRSF4) humanized IgG1 agonistic antibody. |
| M55249 | HFB 3010 | HFB 3010 (HFB 301001) is a novel second-generation fully human IgG1 class OX40 agonistic monoclonal antibody. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
